RxDoctor Payments Data

Udhav Gaitonde, MD

Family Medicine · Durand, MINPI 1407377211

Payments from drug & device makers

$3,190in general payments, 2019–2025

Across 146 payments — averaging $21.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$686
  • Novo Nordisk$560
  • AbbVie$423
  • Amgen$390
  • Lilly USA, LLC$194
  • Otsuka America Pharmaceutical, Inc.$174
  • plus $763 from 19 others

What the payments were for

  • Food & beverage$3,183100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,190 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$35,002
Medicare patients
120
Services billed
381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin45$55,261
XareltoRivaroxaban38$37,084
EliquisApixaban23$30,922
OzempicSemaglutide30$29,996
RybelsusSemaglutide21$27,301
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$22,221
MounjaroTirzepatide22$22,175
JanuviaSitagliptin Phosphate13$16,376
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$11,304
GemtesaVibegron19$8,545
MyrbetriqMirabegron13$7,232
Breo ElliptaFluticasone/Vilanterol14$6,382
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$5,998
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$5,391
Atorvastatin Calcium281$3,877

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$560$57,29751 claims
Boehringer IngelheimJardiance$24$55,26145 claims
PfizerEliquis$110$30,92223 claims
AstraZenecaBreztri Aerosphere$686$22,22136 claims
Lilly USA, LLCMounjaro$194$22,17522 claims
MerckJanuvia$42$16,37613 claims
Sumitomo Pharma America, Inc.Gemtesa$14$8,54519 claims
Astellas Pharma US IncMyrbetriq$38$7,23213 claims
AbbVieSynthroid$423$92618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Durand

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →